{
  "symbol": "DXCM",
  "year": 2023,
  "metrics": {
    "mdna_sentiment": 0.0,
    "outlook_sentiment": 0.2148,
    "forward_ratio": 1.0,
    "hedge_ratio": 0.307
  },
  "top_positive": [
    {
      "sent": "Consolidated Balance Sheets December 31, 2022 2021 (In millions, except par value data) (As Adjusted)* Assets Current assets: Cash and cash equivalents $ 642.3 $ 1,052.6 Short-term marketable securities 1,813.9 1,678.6 Accounts receivable, net 713.3 514.3 Inventory 306.7 357.3 Prepaid and other current assets 192.6 81.6 Total current assets 3,668.8 3,684.4 Property and equipment, net 1,055.6 801.8 Operating lease right-of-use assets 80.0 88.1 Goodwill 25.7 26.5 Intangibles, net 173.3 31.5 Deferred tax assets 341.2 290.5 Other assets 47.1 10.5 Total assets $ 5,391.7 $ 4,933.3 Liabilities and Stockholders\u2019 Equity Current liabilities: Accounts payable and accrued liabilities $ 901.8 $ 573.0 Accrued payroll and related expenses 134.3 125.2 Current portion of long-term senior convertible notes 772.6 \u2014 Short-term operating lease liabilities 20.5 20.5 Deferred revenue 10.1 2.1 Total current liabilities 1,839.3 720.8 Long-term senior convertible notes 1,197.7 1,981.8 Long-term operating lease liabilities 94.6 98.6 Other long-term liabilities 128.3 90.0 Total liabilities 3,259.9 2,891.2 Commitments and contingencies Stockholders\u2019 equity: Preferred stock, $ 0.001 par value, 5.0 million shares authorized; no shares issued and outstanding at December\u00a031, 2022 and December\u00a031, 2021 \u2014 \u2014 Common stock, $ 0.001 par value, 800.0 million shares authorized; 393.2 million and 386.3 million shares issued and outstanding, respectively, at December\u00a031, 2022; and 391.4 million and 388.0 million shares issued and outstanding, respectively, at December\u00a031, 2021 0.4 0.4 Additional paid-in capital 2,258.1 2,108.7 Accumulated other comprehensive income (loss) ( 11.6 ) 0.5 Retained earnings 479.9 138.7 Treasury stock, at cost; 6.9 million shares at December\u00a031, 2022 and 3.4 million shares at December\u00a031, 2021 ( 595.0 ) ( 206.2 ) Total stockholders\u2019 equity 2,131.8 2,042.1 Total liabilities and stockholders\u2019 equity $ 5,391.7 $ 4,933.3 * We adjusted our 2021 amounts to reflect the simplified convertible instruments accounting guidance, which we adopted on a full retrospective basis.",
      "score": 0.9884
    },
    {
      "sent": "Consolidated Balance Sheets December 31, 2022 2021 (In millions, except par value data) (As Adjusted)* Assets Current assets: Cash and cash equivalents $ 642.3 $ 1,052.6 Short-term marketable securities 1,813.9 1,678.6 Accounts receivable, net 713.3 514.3 Inventory 306.7 357.3 Prepaid and other current assets 192.6 81.6 Total current assets 3,668.8 3,684.4 Property and equipment, net 1,055.6 801.8 Operating lease right-of-use assets 80.0 88.1 Goodwill 25.7 26.5 Intangibles, net 173.3 31.5 Deferred tax assets 341.2 290.5 Other assets 47.1 10.5 Total assets $ 5,391.7 $ 4,933.3 Liabilities and Stockholders\u2019 Equity Current liabilities: Accounts payable and accrued liabilities $ 901.8 $ 573.0 Accrued payroll and related expenses 134.3 125.2 Current portion of long-term senior convertible notes 772.6 \u2014 Short-term operating lease liabilities 20.5 20.5 Deferred revenue 10.1 2.1 Total current liabilities 1,839.3 720.8 Long-term senior convertible notes 1,197.7 1,981.8 Long-term operating lease liabilities 94.6 98.6 Other long-term liabilities 128.3 90.0 Total liabilities 3,259.9 2,891.2 Commitments and contingencies Stockholders\u2019 equity: Preferred stock, $ 0.001 par value, 5.0 million shares authorized; no shares issued and outstanding at December\u00a031, 2022 and December\u00a031, 2021 \u2014 \u2014 Common stock, $ 0.001 par value, 800.0 million shares authorized; 393.2 million and 386.3 million shares issued and outstanding, respectively, at December\u00a031, 2022; and 391.4 million and 388.0 million shares issued and outstanding, respectively, at December\u00a031, 2021 0.4 0.4 Additional paid-in capital 2,258.1 2,108.7 Accumulated other comprehensive income (loss) ( 11.6 ) 0.5 Retained earnings 479.9 138.7 Treasury stock, at cost; 6.9 million shares at December\u00a031, 2022 and 3.4 million shares at December\u00a031, 2021 ( 595.0 ) ( 206.2 ) Total stockholders\u2019 equity 2,131.8 2,042.1 Total liabilities and stockholders\u2019 equity $ 5,391.7 $ 4,933.3 * We adjusted our 2021 amounts to reflect the simplified convertible instruments accounting guidance, which we adopted on a full retrospective basis.",
      "score": 0.9884
    },
    {
      "sent": "Consolidated Statements of Comprehensive Income Twelve Months Ended December 31, 2022 2021 2020 (In millions) (As Adjusted)* (As Adjusted)* Net income $ 341.2 $ 216.9 $ 549.7 Other comprehensive income (loss), net of tax: Translation adjustments and other ( 9.8 ) ( 1.0 ) 1.1 Unrealized loss on marketable debt securities ( 2.3 ) ( 1.7 ) ( 0.2 ) Total other comprehensive income (loss), net of tax ( 12.1 ) ( 2.7 ) 0.9 Comprehensive income $ 329.1 $ 214.2 $ 550.6 * We adjusted our 2021 and 2020 amounts to reflect the simplified convertible instruments accou\ned and outstanding at December\u00a031, 2022 and December\u00a031, 2021 \u2014 \u2014 Common stock, $ 0.001 par value, 800.0 million shares authorized; 393.2 million and 386.3 million shares issued and outstanding, respectively, at December\u00a031, 2022; and 391.4 million and 388.0 million shares issued and outstanding, respectively, at December\u00a031, 2021 0.4 0.4 Additional paid-in capital 2,258.1 2,108.7 Accumulated other comprehensive income (loss) ( 11.6 ) 0.5 Retained earnings 479.9 138.7 Treasury stock, at cost; 6.9 million shares at December\u00a031, 2022 and 3.4 million shares at December\u00a031, 2021 ( 595.0 ) ( 206.2 ) Total stockholders\u2019 equity 2,131.8 2,042.1 Total liabilities and stockholders\u2019 equity $ 5,391.7 $ 4,933.3 * We adjusted our 2021 amounts to reflect the simplified convertible instruments accounting guidance, which we adopted on a full retrospective basis.",
      "score": 0.9858
    }
  ],
  "top_negative": [
    {
      "sent": "These include: \u2022 establishment registration and device listing; \u2022 QSR, which requires manufacturers to follow design, testing, control, storage, supplier/contractor selection, complaint handling, documentation and other quality assurance procedures; \u2022 labeling regulations, which prohibit the promotion of products for unapproved or off-label uses or indications and impose other restrictions on labeling, advertising and promotion; \u2022 medical device reporting regulations, which require that manufacturers report to the FDA if a device may have caused or contributed to a death or serious injury or malfunctioned in a way that would likely cause or contribute to a death or serious injury if it were to recur; \u2022 voluntary and mandatory device recalls to address problems when a device is defective and/or could be a risk to health; and \u2022 corrections and removal reporting regulations, which require that manufacturers report to the FDA field corrections and product recalls or removals if undertaken to reduce a risk to health posed by the device or to remedy a violation of the FDCA that may present a risk to health.",
      "score": -0.9837
    },
    {
      "sent": "These include: \u2022 establishment registration and device listing; \u2022 QSR, which requires manufacturers to follow design, testing, control, storage, supplier/contractor selection, complaint handling, documentation and other quality assurance procedures; \u2022 labeling regulations, which prohibit the promotion of products for unapproved or off-label uses or indications and impose other restrictions on labeling, advertising and promotion; \u2022 medical device reporting regulations, which require that manufacturers report to the FDA if a device may have caused or contributed to a death or serious injury or malfunctioned in a way that would likely cause or contribute to a death or serious injury if it were to recur; \u2022 voluntary and mandatory device recalls to address problems when a device is defective and/or could be a risk to health; and \u2022 corrections and removal reporting regulations, which require that manufacturers report to the FDA field corrections and product recalls or removals if undertaken to reduce a risk to health posed by the device or to remedy a violation of the FDCA that may present a risk to health.",
      "score": -0.9837
    },
    {
      "sent": "Later discovery of previously unknown problems with our products, including software bugs, unanticipated adverse events or adverse events of unanticipated severity or frequency, manufacturing problems, or failure to comply with regulatory requirements such as the QSR, MDR reporting, or other post-market requirements may result in restrictions on such products or manufacturing processes, withdrawal of the products from the market, voluntary or mandatory recalls (through corrections or removals), fines, suspension of regulatory approvals, product seizures, injunctions, the imposition of civil or criminal penalties, or criminal prosecution.",
      "score": -0.9694
    }
  ],
  "forward_snippets": [
    "Many of these laws and regulations are subject to change and uncertain or evolving guidance and interpretation, and could result in claims, changes to our business practices, product development impacts, monetary penalties, increased cost of operations, or declines in user growth or engagement, or otherwise harm our business.",
    "Many of these laws and regulations are subject to change and uncertain or evolving guidance and interpretation, and could result in claims, changes to our business practices, product development impacts, monetary penalties, increased cost of operations, or declines in user growth or engagement, or otherwise harm our business.",
    "In June 2018, we received Conformit\u00e9 Europ\u00e9enne Marking, or CE Mark, approval for the G6, which allows us to market the system in the European Union and the countries in Asia and Latin America that recognize the CE Mark, as well as New Zealand, though certain countries may require compliance with certain local administrative requirements and/or additional marketing authorizations (for example, the inclusion of m\nguidance and interpretation, and could result in claims, changes to our business practices, product development impacts, monetary penalties, increased cost of operations, or declines in user growth or engagement, or otherwise harm our business.",
    "As we establish an installed base of customers using our products, we expect to generate an increasing portion of our revenues through recurring sales of our disposable sensors.",
    "As we establish an installed base of customers using our products, we expect to generate an increasing portion of our revenues through recurring sales of our disposable sensors."
  ]
}